Market closed
Pyxis Oncology/$PYXS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pyxis Oncology
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Ticker
$PYXS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
44
Website
Pyxis Oncology Metrics
BasicAdvanced
$66M
-
-$1.32
1.11
-
Price and volume
Market cap
$66M
Beta
1.11
52-week high
$4.61
52-week low
$0.83
Average daily volume
519K
Financial strength
Current ratio
7.491
Quick ratio
7.179
Long term debt to equity
15.528
Total debt to equity
16.729
Management effectiveness
Return on assets (TTM)
-24.77%
Return on equity (TTM)
-62.75%
Valuation
Price to revenue (TTM)
3.873
Price to book
0.55
Price to tangible book (TTM)
0.56
Price to free cash flow (TTM)
-1.08
Growth
Earnings per share change (TTM)
-28.45%
3-year earnings per share growth (CAGR)
-47.11%
What the Analysts think about Pyxis Oncology
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Pyxis Oncology stock.
Pyxis Oncology Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Pyxis Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Pyxis Oncology News
AllArticlesVideos
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
GlobeNewsWire·2 weeks ago
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
GlobeNewsWire·1 month ago
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Pyxis Oncology stock?
Pyxis Oncology (PYXS) has a market cap of $66M as of May 09, 2025.
What is the P/E ratio for Pyxis Oncology stock?
The price to earnings (P/E) ratio for Pyxis Oncology (PYXS) stock is 0 as of May 09, 2025.
Does Pyxis Oncology stock pay dividends?
No, Pyxis Oncology (PYXS) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Pyxis Oncology dividend payment date?
Pyxis Oncology (PYXS) stock does not pay dividends to its shareholders.
What is the beta indicator for Pyxis Oncology?
Pyxis Oncology (PYXS) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.